Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES.

Braffett BH, Lorenzi GM, Cowie CC, Gao X, Bainbridge KE, Cruickshanks KJ, Kramer JR, Gubitosi-Klug RA, Larkin ME, Barnie A, Lachin JM, Schade DS; DCCT/EDIC Research Group.

Endocr Pract. 2019 Aug 14. doi: 10.4158/EP-2019-0193. [Epub ahead of print]

PMID:
31412233
2.

Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664.

Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2019 Aug;42(8):e137. doi: 10.2337/dci19-0026. No abstract available.

PMID:
31332032
3.

Closed testing using surrogate hypotheses with restricted alternatives.

Lachin JM, Bebu I, Larsen MD, Younes N.

PLoS One. 2019 Jul 12;14(7):e0219520. doi: 10.1371/journal.pone.0219520. eCollection 2019.

4.

Immune Complexes and the Risk of CVD in Type 1 Diabetes.

Lopes-Virella MF, Bebu I, Hunt KJ, Virella G, Baker NL, Braffett B, Gao X, Lachin JM; DCCT/EDIC Research Group.

Diabetes. 2019 Sep;68(9):1853-1860. doi: 10.2337/db19-0358. Epub 2019 Jun 19.

PMID:
31217176
5.

Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough?

Gubitosi-Klug RA, Bebu I, White NH, Malone J, Miller R, Lorenzi GM, Hainsworth DP, Trapani VR, Lachin JM, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group*.

Pediatr Diabetes. 2019 Sep;20(6):743-749. doi: 10.1111/pedi.12877. Epub 2019 Jul 9.

PMID:
31206973
6.

Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.

Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2019 Jul;42(7):1284-1289. doi: 10.2337/dc18-1613. Epub 2019 Mar 20.

PMID:
30894365
7.

The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials.

Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, Strowig S, Raskin P, Lachin JM; DCCT/EDIC Research Group.

JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 2):1341-1349. doi: 10.1016/j.jcmg.2019.01.014. Epub 2019 Mar 13.

PMID:
30878435
8.

Risk Factors for Kidney Disease in Type 1 Diabetes.

Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

Diabetes Care. 2019 May;42(5):883-890. doi: 10.2337/dc18-2062. Epub 2019 Mar 4.

PMID:
30833370
9.

Risk Factors for Retinopathy in Type 1 Diabetes: The DCCT/EDIC Study.

Hainsworth DP, Bebu I, Aiello LP, Sivitz W, Gubitosi-Klug R, Malone J, White NH, Danis R, Wallia A, Gao X, Barkmeier AJ, Das A, Patel S, Gardner TW, Lachin JM; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

Diabetes Care. 2019 May;42(5):875-882. doi: 10.2337/dc18-2308. Epub 2019 Mar 4.

PMID:
30833368
10.

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.

Braffett BH, Dagogo-Jack S, Bebu I, Sivitz WI, Larkin M, Kolterman O, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2019 Apr;42(4):657-664. doi: 10.2337/dc18-1574. Epub 2019 Feb 6.

PMID:
30728218
11.

Mediation of the association of smoking and microvascular complications by glycemic control in type 1 diabetes.

Braffett BH, Rice MM, Young HA, Lachin JM.

PLoS One. 2019 Jan 7;14(1):e0210367. doi: 10.1371/journal.pone.0210367. eCollection 2019.

12.

Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.

Claggett B, Lachin JM, Hantel S, Fitchett D, Inzucchi SE, Woerle HJ, George JT, Zinman B.

Circulation. 2018 Oct 9;138(15):1599-1601. doi: 10.1161/CIRCULATIONAHA.118.033810. No abstract available.

PMID:
30354516
13.

Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.

Schade DS, Lorenzi GM, Braffett BH, Gao X, Bainbridge KE, Barnie A, Cruickshanks KJ, Dalton D, Diminick L, Gubitosi-Klug R, Kramer JR, Lachin JM, Larkin ME, Cowie CC; DCCT/EDIC Research Group.

Diabetes Care. 2018 Dec;41(12):2495-2501. doi: 10.2337/dc18-0625. Epub 2018 Sep 25.

PMID:
30254082
14.

What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?

Herman WH, Braffett BH, Kuo S, Lee JM, Brandle M, Jacobson AM, Prosser LA, Lachin JM.

J Diabetes Complications. 2018 Oct;32(10):911-915. doi: 10.1016/j.jdiacomp.2018.05.007. Epub 2018 Jun 12.

15.
16.

Properties of composite time to first event versus joint marginal analyses of multiple outcomes.

Bebu I, Lachin JM.

Stat Med. 2018 Nov 30;37(27):3918-3930. doi: 10.1002/sim.7849. Epub 2018 Jun 28.

PMID:
29956365
17.

Sample size evaluation for a multiply matched case-control study using the score test from a conditional logistic (discrete Cox PH) regression model.

Lachin JM.

Stat Med. 2018 May 10;37(10):1765-1766. doi: 10.1002/sim.7598. Epub 2018 Jan 31. No abstract available.

PMID:
29642274
18.

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.

Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B; EMPA-REG OUTCOME Investigators.

J Am Coll Cardiol. 2018 Jan 23;71(3):364-367. doi: 10.1016/j.jacc.2017.11.022. No abstract available.

19.

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.

Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2018 Mar;41(3):596-603. doi: 10.2337/dc17-1778. Epub 2018 Jan 8.

PMID:
29311155
20.

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.

Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM.

Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.

PMID:
29203583
21.

Biomarkers of tubulointerstitial damage and function in type 1 diabetes.

de Boer IH, Gao X, Bebu I, Hoofnagle AN, Lachin JM, Paterson A, Perkins BA, Saenger AK, Steffes MW, Zinman B, Molitch ME.

BMJ Open Diabetes Res Care. 2017 Nov 14;5(1):e000461. doi: 10.1136/bmjdrc-2017-000461. eCollection 2017.

22.

Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777-783.

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Nov;40(11):e165-e166. doi: 10.2337/dci17-0038. No abstract available.

23.

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE; EMPA-REG OUTCOME® trial investigators.

Eur Heart J. 2018 Feb 1;39(5):363-370. doi: 10.1093/eurheartj/ehx511.

PMID:
29020355
24.

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.

Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6.

PMID:
28986504
25.

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.

Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators.

Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.

PMID:
28904068
26.

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.

Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED; TECOS Study Group.

Hypertension. 2017 Nov;70(5):907-914. doi: 10.1161/HYPERTENSIONAHA.117.09482. Epub 2017 Aug 28.

27.

The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study.

Bebu I, Braffett BH, Pop-Busui R, Orchard TJ, Nathan DM, Lachin JM; DCCT/EDIC Research Group.

Diabetologia. 2017 Oct;60(10):2084-2091. doi: 10.1007/s00125-017-4374-4. Epub 2017 Jul 16.

28.

Frequency of Evidence-Based Screening for Diabetic Retinopathy.

Nathan DM, Bebu I, Lachin JM.

N Engl J Med. 2017 Jul 13;377(2):195. doi: 10.1056/NEJMc1706322. No abstract available.

PMID:
28700836
29.

Refining Measurement of Hemoglobin A1c.

Sacks DB, Bebu I, Lachin JM.

Clin Chem. 2017 Sep;63(9):1433-1435. doi: 10.1373/clinchem.2016.268573. Epub 2017 Jun 20. No abstract available.

30.

Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study.

Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.

Diabetes Care. 2017 Aug;40(8):1010-1016. doi: 10.2337/dc16-2723. Epub 2017 May 26.

31.

Optimal screening schedules for disease progression with application to diabetic retinopathy.

Bebu I, Lachin JM.

Biostatistics. 2018 Jan 1;19(1):1-13. doi: 10.1093/biostatistics/kxx009.

32.

Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.

DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM.

N Engl J Med. 2017 Apr 20;376(16):1507-1516. doi: 10.1056/NEJMoa1612836.

33.

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial.

Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, Nathan DM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Jun;40(6):777-783. doi: 10.2337/dc16-2426. Epub 2017 Apr 12.

34.

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC; EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients).

Stroke. 2017 May;48(5):1218-1225. doi: 10.1161/STROKEAHA.116.015756. Epub 2017 Apr 6.

35.

Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes.

Guglielmi C, Del Toro R, Lauria A, Maurizi AR, Fallucca S, Cappelli A, Angeletti S, Lachin JM, Pozzilli P.

Diabetes Metab Res Rev. 2017 Sep;33(6). doi: 10.1002/dmrr.2899. Epub 2017 May 9.

PMID:
28371189
36.

Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study.

Soliman EZ, Backlund JC, Bebu I, Orchard TJ, Zinman B, Lachin JM; DCCT/EDIC Research Group.

Diabetes Care. 2017 Jun;40(6):793-799. doi: 10.2337/dc16-2050. Epub 2017 Mar 16.

37.

Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.

de Boer IH, Gao X, Cleary PA, Bebu I, Lachin JM, Molitch ME, Orchard T, Paterson AD, Perkins BA, Steffes MW, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1969-1977. Epub 2016 Oct 24.

38.

Pancreatic Safety of Sitagliptin in the TECOS Study.

Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14.

39.

Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).

Orchard TJ, Backlund JC, Costacou T, Cleary P, Lopes-Virella M, Levy AP, Lachin JM; DCCT/EDIC Research Group.

J Diabetes Complications. 2016 Nov - Dec;30(8):1577-1584. doi: 10.1016/j.jdiacomp.2016.07.014. Epub 2016 Jul 25.

40.

Significance of Epicardial and Intrathoracic Adipose Tissue Volume among Type 1 Diabetes Patients in the DCCT/EDIC: A Pilot Study.

Darabian S, Backlund JY, Cleary PA, Sheidaee N, Bebu I, Lachin JM, Budoff MJ; DCCT/EDIC Research Group.

PLoS One. 2016 Jul 26;11(7):e0159958. doi: 10.1371/journal.pone.0159958. eCollection 2016.

41.

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.

JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103.

PMID:
27437883
42.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators.

N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.

43.

Probabilistic measures of cost-effectiveness.

Bebu I, Mathew T, Lachin JM.

Stat Med. 2016 Sep 30;35(22):3976-86. doi: 10.1002/sim.6987. Epub 2016 May 18.

PMID:
27194076
44.

Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort.

Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):E3002-11. doi: 10.1073/pnas.1603712113. Epub 2016 May 9.

45.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Zinman B, Lachin JM, Inzucchi SE.

N Engl J Med. 2016 Mar 17;374(11):1094. doi: 10.1056/NEJMc1600827. No abstract available.

PMID:
26981940
46.

Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study.

Soliman EZ, Backlund JY, Bebu I, Li Y, Zhang ZM, Cleary PA, Lachin JM; DCCT/EDIC Research Group.

J Am Heart Assoc. 2016 Mar 14;5(3):e002882. doi: 10.1161/JAHA.115.002882.

47.

Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes.

Sell DR, Sun W, Gao X, Strauch C, Lachin JM, Cleary PA, Genuth S; DCCT/EDIC Research Group, Monnier VM.

Cardiovasc Diabetol. 2016 Feb 11;15:30. doi: 10.1186/s12933-016-0343-3.

48.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators.

Eur Heart J. 2016 May 14;37(19):1526-34. doi: 10.1093/eurheartj/ehv728. Epub 2016 Jan 26.

49.

Data sharing is desirable, but benefits should not be exaggerated.

Nathan DM, Genuth SM, Zinman B, Lachin JM.

BMJ. 2015 Oct 21;351:h5508. doi: 10.1136/bmj.h5508. No abstract available.

PMID:
26489751
50.

Erratum to: Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.

Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S; DCCT/EDIC Research Group.

Cardiovasc Diabetol. 2015 Oct 9;14:138. doi: 10.1186/s12933-015-0295-z. No abstract available.

Supplemental Content

Loading ...
Support Center